People · Operator
Named in public records as an officer, director or promoter · active 2018–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Kriya Therapeutics, Inc. | — | Biotechnology | Series D+ | $870.3M | $2.5B | 2021 |
| Vir Biotechnology, Inc. | — | Biotechnology | Series D+ | $348.4M | $1.3B | 2020 |
| Innovate Biopharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $154.0M | $791.8M | 2018 |
| Pain Therapeutics Inc | — | Pharmaceuticals | Seed | $1.1M | $42.1M | 2018 |
Saira Ramasastry at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Saira Ramasastry on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 1 | 22 |
| Kristina Burow | 1 | 16 |
| Michael O'Donnell | 1 | 11 |
| Robert More | 1 | 7 |
| Vicki Sato | 1 | 6 |
| Sandeep Laumas | 1 | 6 |
| Anthony Maida | 1 | 5 |
| George Scangos | 1 | 4 |
| Thomas Daniel | 1 | 4 |
| Roger Jeffs | 1 | 3 |
| Christopher Prior | 1 | 3 |
| Edward J. Sitar | 1 | 3 |
| Dipchand Nishar | 1 | 3 |
| Dana Johnson | 1 | 3 |
| DANIEL CHEN | 1 | 3 |
| Robert Perez | 1 | 3 |
| Jay Madan | 1 | 2 |
| Philip Sharp | 1 | 2 |
| James Momtazee | 1 | 2 |
| Ilan Oren | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.